戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rmediary metabolism in patients treated with beta-lapachone.
2 dependent apoptosis with PARP inhibitors and beta-lapachone.
3 nyboquinone-induced lethality, as noted with beta-lapachone.
4 1-dependent manner with greater potency than beta-lapachone.
5 ion path and in a later transition state for beta-lapachone.
6  of action and optimal therapeutic window of beta-lapachone.
7 o ROS formation and all cytotoxic effects of beta-lapachone.
8 NQO1) substantially enhances the toxicity of beta-lapachone.
9 must be added either simultaneously or after beta-lapachone.
10 n of Ipe extract caused the incorporation of beta-lapachone (137 mg/L) into the beverage and promoted
11          To study the mechanism of action of beta-lapachone, a series of beta-lapachone and related n
12                                              beta-Lapachone activates a novel apoptotic response in a
13 he tumor-selective overexpression of the key beta-lapachone activating enzymes NQO1 and 5-LO, the TME
14 hydrocostus lactone (DHL), parthenolide, and beta-lapachone, all of which are innocuous individually
15                                              beta-Lapachone, an effective chemotherapeutic and radios
16 arity between menadione, a para-quinone, and beta-lapachone, an ortho-quinone, together with their si
17 RN) is constructed by the coencapsulation of beta-lapachone and a reactive-oxygen-species (ROS)-respo
18                      In preliminary studies, beta-lapachone and related naphthoquinones are found to
19        Poisoning of topoisomerase IIalpha by beta-lapachone and related naphthoquinones is independen
20 ism of action of beta-lapachone, a series of beta-lapachone and related naphthoquinones were synthesi
21                                     However, beta-lapachone and related naphthoquinones, like menadio
22 ture after treatment with the combination of beta-lapachone and taxol, two low molecular mass compoun
23 KP372-1 is ~ 10- to 20-fold more potent than beta-lapachone, another NQO1 substrate, against pancreat
24                     When PARP inhibitors and beta-lapachone are combined, synergistic antitumor activ
25                                              Beta-lapachone (beta-lap) affects a number of enzymes in
26                                              Beta-lapachone (beta-lap) is a novel anticancer drug tha
27                                              beta-lapachone (beta-lap) is the first chemotherapeutic
28                                              beta-Lapachone (beta-Lap) triggers apoptosis in a number
29                                    Recently, beta-lapachone (beta-lap) was shown to be highly efficac
30   Application of quinone drugs, particularly beta-lapachone (beta-lap), under normoxic and hypoxic co
31 produced by a redox-cycling anticancer drug, beta-lapachone (beta-lap).
32                                              beta-Lapachone (beta-lap; also known as ARQ 501), curren
33             The clinical experimental agent, beta-lapachone (beta-lap; Arq 501), can act as a potent
34 nt antitumor efficacy of deoxynyboquinone to beta-lapachone, but at a 6-fold greater potency.
35 iochemical studies suggest that reduction of beta-lapachone by NQO1 leads to a futile cycling between
36                                              beta-Lapachone causes cell-cycle delays in late G(1) and
37 of an ortho-quinone prodrug, a propargylated beta-lapachone derivative, through a palladium-mediated
38 al studies of the reduction reactions in nor-beta-lapachone derivatives including a nitro redox cente
39         Consistent with the previous report, beta-lapachone does not induce topoisomerase I-mediated
40 ased apoptotic responses and lethality after beta-lapachone exposure.
41                                    Releasing beta-lapachone first from the CARNs selectively increase
42       ortho-Quinone natural products such as beta-lapachone have exhibited great therapeutic potentia
43 orrelated with sensitivity to a 4-h pulse of beta-lapachone in a panel of breast cancer cell lines, a
44 ate that the most efficacious strategy using beta-lapachone in chemotherapy was to deliver the drug i
45 e elucidation of an intracellular target for beta-lapachone in tumor cells.
46 e.g., the environmental toxins menadione and beta-lapachone (in vivo IC(50) = 0.45 muM) also cause in
47                                 Kinetically, beta-lapachone-induced cell death was characterized by t
48                                              beta-Lapachone-induced high mobility group box 1 (HMGB1)
49                                              Beta-lapachone-induced PARP-1 hyperactivation, nucleotid
50 2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (beta-lapachone) inhibits DNA topoisomerase I by a mechan
51 nones form adducts with mercaptoethanol, and beta-lapachone is 10-fold more reactive.
52                          We report here that beta-lapachone is a potent, reversible CE inhibitor with
53                                              beta-Lapachone is an ortho-naphthoquinone natural produc
54                                              beta-Lapachone is bioactivated by NAD(P)H:quinone oxidor
55                                              beta-Lapachone is catalyzed and bioactivated by NQO1 to
56                                              beta-Lapachone killed cells in a tumorselective manner a
57 S dual-responsive nanomedicine consisting of beta-lapachone (Lap), a pH-responsive polymer, and a ROS
58 s were killed in an NQO1-dependent manner by beta-lapachone (LD50, approximately 4 microM) with a min
59 activation-mediated programmed necrosis with beta-lapachone monotherapy to synergistic tumor-selectiv
60 mparing equivalent points on both alpha- and beta-lapachone potential energy surfaces (PES), accordin
61                         Previously developed beta-lapachone prodrugs suffered from suboptimal release
62 t TOP1 inhibition with camptothecin (CPT) or beta-Lapachone results in a significant reduction in vir
63 droxybenzyl (PHB) moiety alkylated to one of beta-lapachone's carbonyls via an indium-mediated Barbie
64                                              beta-Lapachone's therapeutic efficacy partially stems fr
65                           Here, we show that beta-lapachone selectively induces apoptosis in cancer c
66 ork explores the development of an optimized beta-lapachone small molecule prodrug platform that util
67                              Agents, such as beta-lapachone, that target the redox enzyme, NAD(P)H:qu
68                               In contrast to beta-lapachone, the designed prodrug remained intact in
69                         After treatment with beta-lapachone, there was a change in (64)Cu-ATSM signal
70                     Conjugation of protected beta-lapachone to Gem-IgG1 antibodies, which contain the
71 ed NQO1-expressing cells from all aspects of beta-lapachone toxicity.
72 markers useful for in vivo dose responses of beta-lapachone treatment in humans, avoiding toxic side
73 oxidative flux due to NAD(+) depletion after beta-lapachone treatment of NQO1+ human pancreatic cance
74 ent may have the potential to synergize with beta-lapachone treatment, creating unique NQO1-selective
75 uvate dehydrogenase), were down-regulated by beta-lapachone treatment.
76 pendent protease, calpain, is observed after beta-lapachone treatment.
77 , we demonstrate that NQO1-targeting prodrug beta-lapachone triggers tumor-selective innate sensing l
78 ed the strategy for intracellular release of beta-lapachone upon antibody-mediated delivery.
79 ation of the electrophilic quinone moiety of beta-lapachone via a C(sp(3))-C(sp(3)) bond to a coumari
80   The regioselective formation of alpha- and beta-lapachone via hetero-Diels-Alder reactions was inve
81 n assays in cells, the protected analogue of beta-lapachone was activated by nontoxic amounts of nano
82         By using a 5-lipoxygenase modulator, beta-lapachone, we created cathepsin-B-cleavable quinone